Compare IHRT & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHRT | DBVT |
|---|---|---|
| Founded | 1974 | 2002 |
| Country | United States | France |
| Employees | 10100 | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.1M | 508.8M |
| IPO Year | 2019 | N/A |
| Metric | IHRT | DBVT |
|---|---|---|
| Price | $3.85 | $12.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.50 | ★ $15.85 |
| AVG Volume (30 Days) | ★ 2.8M | 142.0K |
| Earning Date | 11-10-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,856,033,000.00 | $5,502,000.00 |
| Revenue This Year | $0.22 | $1,743.46 |
| Revenue Next Year | $6.06 | $1,045.66 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.39 | N/A |
| 52 Week Low | $0.95 | $2.74 |
| 52 Week High | $4.77 | $18.00 |
| Indicator | IHRT | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 43.16 |
| Support Level | $3.65 | $12.70 |
| Resistance Level | $3.97 | $13.60 |
| Average True Range (ATR) | 0.26 | 0.93 |
| MACD | -0.07 | -0.12 |
| Stochastic Oscillator | 26.84 | 22.09 |
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.